Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-1,130
Closed -$251K 130
2023
Q2
$251K Sell
1,130
-1,285
-53% -$298K ﹤0.01% 557
2023
Q1
$584K Buy
+2,415
New +$593K ﹤0.01% 565
2022
Q3
Sell
-22,242
Closed -$5.41M 623
2022
Q2
$5.41M Sell
22,242
-24,572
-52% -$6.02M 0.02% 237
2022
Q1
$11.3M Buy
46,814
+39,703
+558% +$9.12M 0.04% 138
2021
Q4
$1.6M Buy
+7,111
New +$1.5M 0.01% 367

Other funds holding AMGN

Brookfield Corp's AMGN Position: Q3 2023 in Review

Brookfield Corp sold out of Amgen (AMGN) in Q3 2023, closing a stake of 1,130 shares — an estimated $251K sold.

Brookfield Corp first reported a position in AMGN in Q4 2021 and held it in 5 quarters. The position peaked at $11.3M in Q1 2022. 2,502 funds tracked by Wall St. Rank hold AMGN as of Q3 2023.

  • Brookfield Corp reported no remaining Amgen position as of Q3 2023 after selling out during the quarter.
  • Brookfield Corp sold 1,130 Amgen shares in Q3 2023, an estimated $251K.
  • Brookfield Corp first reported a position in Amgen in Q4 2021 and held it in 5 quarters.
  • Brookfield Corp's Amgen position peaked at $11.3M in Q1 2022.
  • 2,502 funds tracked by Wall St. Rank held Amgen as of Q3 2023.

Based on Brookfield Corp's 13F filing for Q3 2023, filed 14 Nov 2023.